The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Real-world outcomes of patients with MF treated with fedratinib post-ruxolitinib discontinuation
Francesco Passamonti, MD, University of Insubria, Varese, Italy, shares the results of a real-world studying investigating the efficacy of fedratinib in patients with primary myelofibrosis who have been treated with fedratinib after ruxolitinib discontinuation. The study demonstrated a survival advantage for patients who were treated with fedratinib versus those who weren’t after ruxolitinib discontinuation. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
